Stem Cell Clinic

COVID-19 Impact on Platelet Rich Plasma and Stem Cell Alopecia Treatment Identify Which Types of Companies Could Potentially Benefit or Loose out…

Complete study of the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Platelet Rich Plasma and Stem Cell Alopecia Treatment industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Platelet Rich Plasma and Stem Cell Alopecia Treatment production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

Key companies operating in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market include _Kerastem, Eclipse, Regen Lab SA, Stemcell Technologies, RepliCel Life Sciences, Histogen, Glofinn Oy., Platelet Rich Plasma and Stem Cell Alopecia Treatment

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/index/detail/1658983/global-platelet-rich-plasma-and-stem-cell-alopecia-treatment-market

Segmental Analysis

The report has classified the global Platelet Rich Plasma and Stem Cell Alopecia Treatment industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Platelet Rich Plasma and Stem Cell Alopecia Treatment manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Platelet Rich Plasma and Stem Cell Alopecia Treatment industry.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Segment By Type:

, Androgenic Alopecia, Congenital Alopecia, Cicatricial Or Scarring Alopecia

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Segment By Application:

, Hospital, Dermatology Clinic, Other

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market include _Kerastem, Eclipse, Regen Lab SA, Stemcell Technologies, RepliCel Life Sciences, Histogen, Glofinn Oy., Platelet Rich Plasma and Stem Cell Alopecia Treatment

Key questions answered in the report:

Enquire Customization in The Report: https://www.qyresearch.com/customize-request/form/1658983/global-platelet-rich-plasma-and-stem-cell-alopecia-treatment-market

TOC

1 Study Coverage 1.1 Platelet Rich Plasma and Stem Cell Alopecia Treatment Product Introduction 1.2 Market Segments 1.3 Key Platelet Rich Plasma and Stem Cell Alopecia Treatment Manufacturers Covered: Ranking by Revenue 1.4 Market by Type 1.4.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Growth Rate by Type 1.4.2 Androgenic Alopecia 1.4.3 Congenital Alopecia 1.4.4 Cicatricial Or Scarring Alopecia 1.5 Market by Application 1.5.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Growth Rate by Application 1.5.2 Hospital 1.5.3 Dermatology Clinic 1.5.4 Other 1.6 Coronavirus Disease 2019 (Covid-19): Platelet Rich Plasma and Stem Cell Alopecia Treatment Industry Impact 1.6.1 How the Covid-19 is Affecting the Platelet Rich Plasma and Stem Cell Alopecia Treatment Industry 1.6.1.1 Platelet Rich Plasma and Stem Cell Alopecia Treatment Business Impact Assessment Covid-19 1.6.1.2 Supply Chain Challenges 1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products 1.6.2 Market Trends and Platelet Rich Plasma and Stem Cell Alopecia Treatment Potential Opportunities in the COVID-19 Landscape 1.6.3 Measures / Proposal against Covid-19 1.6.3.1 Government Measures to Combat Covid-19 Impact 1.6.3.2 Proposal for Platelet Rich Plasma and Stem Cell Alopecia Treatment Players to Combat Covid-19 Impact 1.7 Study Objectives 1.8 Years Considered 2 Executive Summary 2.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Estimates and Forecasts 2.1.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue 2015-2026 2.1.2 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales 2015-2026 2.2 Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size by Region: 2020 Versus 2026 2.2.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Retrospective Market Scenario in Sales by Region: 2015-2020 2.2.2 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Retrospective Market Scenario in Revenue by Region: 2015-2020 3 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Competitor Landscape by Players 3.1 Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Manufacturers 3.1.1 Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Manufacturers (2015-2020) 3.1.2 Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Market Share by Manufacturers (2015-2020) 3.2 Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Manufacturers 3.2.1 Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Manufacturers (2015-2020) 3.2.2 Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Share by Manufacturers (2015-2020) 3.2.3 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Concentration Ratio (CR5 and HHI) (2015-2020) 3.2.4 Global Top 10 and Top 5 Companies by Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue in 2019 3.2.5 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Platelet Rich Plasma and Stem Cell Alopecia Treatment Price by Manufacturers 3.4 Platelet Rich Plasma and Stem Cell Alopecia Treatment Manufacturing Base Distribution, Product Types 3.4.1 Platelet Rich Plasma and Stem Cell Alopecia Treatment Manufacturers Manufacturing Base Distribution, Headquarters 3.4.2 Manufacturers Platelet Rich Plasma and Stem Cell Alopecia Treatment Product Type 3.4.3 Date of International Manufacturers Enter into Platelet Rich Plasma and Stem Cell Alopecia Treatment Market 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size by Type (2015-2020) 4.1.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Type (2015-2020) 4.1.2 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Type (2015-2020) 4.1.3 Platelet Rich Plasma and Stem Cell Alopecia Treatment Average Selling Price (ASP) by Type (2015-2026) 4.2 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast by Type (2021-2026) 4.2.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Forecast by Type (2021-2026) 4.2.2 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Forecast by Type (2021-2026) 4.2.3 Platelet Rich Plasma and Stem Cell Alopecia Treatment Average Selling Price (ASP) Forecast by Type (2021-2026) 4.3 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Breakdown Data by Application (2015-2026) 5.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size by Application (2015-2020) 5.1.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Application (2015-2020) 5.1.2 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Application (2015-2020) 5.1.3 Platelet Rich Plasma and Stem Cell Alopecia Treatment Price by Application (2015-2020) 5.2 Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast by Application (2021-2026) 5.2.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Forecast by Application (2021-2026) 5.2.2 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Forecast by Application (2021-2026) 5.2.3 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Price Forecast by Application (2021-2026) 6 North America 6.1 North America Platelet Rich Plasma and Stem Cell Alopecia Treatment by Country 6.1.1 North America Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Country 6.1.2 North America Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Country 6.1.3 U.S. 6.1.4 Canada 6.2 North America Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Type 6.3 North America Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Application 7 Europe 7.1 Europe Platelet Rich Plasma and Stem Cell Alopecia Treatment by Country 7.1.1 Europe Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Country 7.1.2 Europe Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Country 7.1.3 Germany 7.1.4 France 7.1.5 U.K. 7.1.6 Italy 7.1.7 Russia 7.2 Europe Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Type 7.3 Europe Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Application 8 Asia Pacific 8.1 Asia Pacific Platelet Rich Plasma and Stem Cell Alopecia Treatment by Region 8.1.1 Asia Pacific Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Region 8.1.2 Asia Pacific Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Region 8.1.3 China 8.1.4 Japan 8.1.5 South Korea 8.1.6 India 8.1.7 Australia 8.1.8 Taiwan 8.1.9 Indonesia 8.1.10 Thailand 8.1.11 Malaysia 8.1.12 Philippines 8.1.13 Vietnam 8.2 Asia Pacific Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Type 8.3 Asia Pacific Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Application 9 Latin America 9.1 Latin America Platelet Rich Plasma and Stem Cell Alopecia Treatment by Country 9.1.1 Latin America Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Country 9.1.2 Latin America Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Country 9.1.3 Mexico 9.1.4 Brazil 9.1.5 Argentina 9.2 Central & South America Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Type 9.3 Central & South America Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Application 10 Middle East and Africa 10.1 Middle East and Africa Platelet Rich Plasma and Stem Cell Alopecia Treatment by Country 10.1.1 Middle East and Africa Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales by Country 10.1.2 Middle East and Africa Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Country 10.1.3 Turkey 10.1.4 Saudi Arabia 10.1.5 U.A.E 10.2 Middle East and Africa Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Type 10.3 Middle East and Africa Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Facts & Figures by Application 11 Company Profiles 11.1 Kerastem 11.1.1 Kerastem Corporation Information 11.1.2 Kerastem Description, Business Overview and Total Revenue 11.1.3 Kerastem Sales, Revenue and Gross Margin (2015-2020) 11.1.4 Kerastem Platelet Rich Plasma and Stem Cell Alopecia Treatment Products Offered 11.1.5 Kerastem Recent Development 11.2 Eclipse 11.2.1 Eclipse Corporation Information 11.2.2 Eclipse Description, Business Overview and Total Revenue 11.2.3 Eclipse Sales, Revenue and Gross Margin (2015-2020) 11.2.4 Eclipse Platelet Rich Plasma and Stem Cell Alopecia Treatment Products Offered 11.2.5 Eclipse Recent Development 11.3 Regen Lab SA 11.3.1 Regen Lab SA Corporation Information 11.3.2 Regen Lab SA Description, Business Overview and Total Revenue 11.3.3 Regen Lab SA Sales, Revenue and Gross Margin (2015-2020) 11.3.4 Regen Lab SA Platelet Rich Plasma and Stem Cell Alopecia Treatment Products Offered 11.3.5 Regen Lab SA Recent Development 11.4 Stemcell Technologies 11.4.1 Stemcell Technologies Corporation Information 11.4.2 Stemcell Technologies Description, Business Overview and Total Revenue 11.4.3 Stemcell Technologies Sales, Revenue and Gross Margin (2015-2020) 11.4.4 Stemcell Technologies Platelet Rich Plasma and Stem Cell Alopecia Treatment Products Offered 11.4.5 Stemcell Technologies Recent Development 11.5 RepliCel Life Sciences 11.5.1 RepliCel Life Sciences Corporation Information 11.5.2 RepliCel Life Sciences Description, Business Overview and Total Revenue 11.5.3 RepliCel Life Sciences Sales, Revenue and Gross Margin (2015-2020) 11.5.4 RepliCel Life Sciences Platelet Rich Plasma and Stem Cell Alopecia Treatment Products Offered 11.5.5 RepliCel Life Sciences Recent Development 11.6 Histogen 11.6.1 Histogen Corporation Information 11.6.2 Histogen Description, Business Overview and Total Revenue 11.6.3 Histogen Sales, Revenue and Gross Margin (2015-2020) 11.6.4 Histogen Platelet Rich Plasma and Stem Cell Alopecia Treatment Products Offered 11.6.5 Histogen Recent Development 11.7 Glofinn Oy. 11.7.1 Glofinn Oy. Corporation Information 11.7.2 Glofinn Oy. Description, Business Overview and Total Revenue 11.7.3 Glofinn Oy. Sales, Revenue and Gross Margin (2015-2020) 11.7.4 Glofinn Oy. Platelet Rich Plasma and Stem Cell Alopecia Treatment Products Offered 11.7.5 Glofinn Oy. Recent Development 11.1 Kerastem 11.1.1 Kerastem Corporation Information 11.1.2 Kerastem Description, Business Overview and Total Revenue 11.1.3 Kerastem Sales, Revenue and Gross Margin (2015-2020) 11.1.4 Kerastem Platelet Rich Plasma and Stem Cell Alopecia Treatment Products Offered 11.1.5 Kerastem Recent Development 12 Future Forecast by Regions (Countries) (2021-2026) 12.1 Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Estimates and Projections by Region 12.1.1 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Forecast by Regions 2021-2026 12.1.2 Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Forecast by Regions 2021-2026 12.2 North America Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast (2021-2026) 12.2.1 North America: Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Forecast (2021-2026) 12.2.2 North America: Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Forecast (2021-2026) 12.2.3 North America: Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast by Country (2021-2026) 12.3 Europe Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast (2021-2026) 12.3.1 Europe: Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Forecast (2021-2026) 12.3.2 Europe: Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Forecast (2021-2026) 12.3.3 Europe: Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast by Country (2021-2026) 12.4 Asia Pacific Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast (2021-2026) 12.4.1 Asia Pacific: Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Forecast (2021-2026) 12.4.2 Asia Pacific: Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Forecast (2021-2026) 12.4.3 Asia Pacific: Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast by Region (2021-2026) 12.5 Latin America Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast (2021-2026) 12.5.1 Latin America: Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Forecast (2021-2026) 12.5.2 Latin America: Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Forecast (2021-2026) 12.5.3 Latin America: Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast by Country (2021-2026) 12.6 Middle East and Africa Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast (2021-2026) 12.6.1 Middle East and Africa: Platelet Rich Plasma and Stem Cell Alopecia Treatment Sales Forecast (2021-2026) 12.6.2 Middle East and Africa: Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue Forecast (2021-2026) 12.6.3 Middle East and Africa: Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast by Country (2021-2026) 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis 13.1 Market Opportunities and Drivers 13.2 Market Challenges 13.3 Market Risks/Restraints 13.4 Porters Five Forces Analysis 13.5 Primary Interviews with Key Platelet Rich Plasma and Stem Cell Alopecia Treatment Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis 14.1 Value Chain Analysis 14.2 Platelet Rich Plasma and Stem Cell Alopecia Treatment Customers 14.3 Sales Channels Analysis 14.3.1 Sales Channels 14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix 16.1 Research Methodology 16.1.1 Methodology/Research Approach 16.1.2 Data Source 16.2 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

View post:
COVID-19 Impact on Platelet Rich Plasma and Stem Cell Alopecia Treatment Identify Which Types of Companies Could Potentially Benefit or Loose out...

Astrocyte-to-Neuron Method Reverses Neurodegeneration in Mice – The Scientist

Turning off just one factor in the brains astrocyte cells is sufficient to convert them into neurons in live mice, according to a paper published in Nature today (June 24) and one this spring by another research team in Cell. By flipping this cellular identity switch, researchers have, to some extent, been able to reverse the neuron loss and motor deficits caused by a Parkinsons-like illness. Not everyone is entirely convinced by the claims.

I think this is very exciting work, says Pennsylvania State Universitys Gong Chen of the Nature paper. It reaffirms that using the brains internal glial cells to regenerate new neurons is a really new avenue for the treatment of brain disorders, he continues. Chen, who is also based at Jinan University and is the chief scientific officer for NeuExcella company developing astrocyte-to-neuron conversion therapieshas performed such conversions in the living mouse brain by a different method but was not involved in the new study.

In Parkinsons disease, dopaminergic neurons within the brains substantia nigraa region in the midbrain involved in movement and rewardgradually die. This results in a deterioration of motor control, characterized by tremors and other types of dyskinesia, with other faculties such as cognition and mood sometimes affected too, especially at later stages of the disease. While treatments to boost diminishing dopamine levels, such as the drug levodopa, can ameliorate symptoms, none can stop the underlying disease process that relentlessly eats away at the patients neurological functions and quality of life.

In the search for disease-modifying therapies, researchers are investigating ways to regenerate or replace the missing neurons. One strategy is to inject stem cellderived neurons into the brain. While this approach, using donor stem cells, is already in a clinical trial, it is far from ideal. The use of donor cells runs the risk of potential immune rejection. On the other hand, using a patients own cells would be costly and time-consuming.

Another approach gaining momentum is to directly transform non-neuronal cells in the midbrain into neurons, which in principle should be simpler and faster than injecting lab-grown neurons. Chen and colleagues have shown that boosting the production of two transcription factors that induce neurogenesisNeurod1 and Dlx2in the brains of mice can convert astrocytes into GABAergic neurons, while others have shown a cocktail of three neurogenic transcription factors can convert astrocytes into dopaminergic neurons in mouse brains.

Instead of adding transcription factors, Xiang-Dong Fu of the University of California, San Diego, and colleagues new approach relies on removing an inhibitor of neurogenesis. Work from his lab had shown that the RNA binding protein PTB prevents the activation of neuronal factors in non-neuronal cells and that deleting it could convert fibroblasts into neurons in culture. Its like a key, he says. You . . . turn the machine on and then you dont need it anymore. Now, Fus group shows in Nature that the approach works directly in the living brain.

Using genetically engineered mice in which astrocyte-specific production of PTB could be switched off at will by injecting a silencing RNA, the team observed that several weeks after PTB depletion, the cells began producing neuronal markers, with the number of ex-astrocytes producing such markers increasing as the weeks went by. Interestingly, injections at different sites in the brain induced different types of neuronswith injections to the substantia nigra producing the highest abundance of dopaminergic neurons. This suggested that while PTB inhibition enabled neuronal conversion, unknown factors within the astrocytes themselves, or their surrounding environment, influenced the neuronal subtype they became. The team went on to show that the converted cells could innervate other brain regions and could form functional synapses.

The team then tested its method in mice whose substantiae nigrae were injected with 6-hydroxydopaminea dopamine analog toxic to dopaminergic neuronsto mimic Parksinons disease. They showed that astrocyte-specific PTB depletion in these mice boosted the numbers of dopamine neurons and the production of dopamine itself, and improved the animals motor functions within three months of the treatment. Animals that did not receive PTB-depletion treatment showed poorer limb use and increased rotational movementsboth standard measures of motor function impairments caused by dopaminergic neuron losscompared with treated animals. The recent paper in Cell by an independent group has shown similar results.

The results . . . present intriguing possibilities for cell replacement strategies, Marina Emborg, a Parkinsons disease researcher at the University of Wisconsin-Madison who was not involved in the studies, writes in an email to The Scientist. The safe clinical translation of this method will need to consider whether the number of astrocytes present in the [patient] brain is enough for effective cell replacement and whether shifting astrocytes into neurons affects brain homeostasis. Also, the researchers will need to assess whether the changed cells remain with a neuronal phenotype and for how long they survive, she adds.

The papers reports of cell transformation dont convince Ole Isacson of Harvard Medical School who works on stem cellderived neurons for treating Parkinsons disease. Turning astrocytes into neurons is something a lot of scientists would want to do, he says, but it is possible what the scientists are calling astrocyte-derived neurons are actually preexisting neurons. The astrocyte-specific machinery of the teams transgenic mice might to some extent leak into surrounding neurons, he says, giving such neurons the appearance of having once been astrocytes. He also says he thinks the teams should test their approaches in a range of robust Parkinsons disease models.

While Fu is convinced his cells are the real deal, there is one problem he admits the approach faces: that it didnt work as effectively in older animals as in younger ones. Experiments in young mice are all very well, but Parkinsons disease affects the elderly, says Chen, so showing the cells can still be converted at older ages, is a critical thing.

H. Qian et al., Reversing a model of Parkinsons disease with in situ converted nigral neurons,Nature, doi:10.1038/s41586-020-2388-4, 2020.

H. Zhou et al., Glia-to-neuron conversion by CRISPR-CasRx alleviates symptoms of neurological disease in mice,Cell, doi:10.1016/j.cell.2020.03.024, 2020.

Read more from the original source:
Astrocyte-to-Neuron Method Reverses Neurodegeneration in Mice - The Scientist

Survey: Impact Of Covid-19 On Media for Stem Cell Market 2020 Industry Outlook, Opportunities in Market and Expansion By 2026 – Cole of Duty

The thorough information about the Media for Stem Cell Market Report comprises the global data, figures, and essential statistics. However, this report also has information about the year 2020 until the forecasting for the year 2026. Moreover, the effects of the pandemic COVID-19 on the industry are also incorporated in this report on the industry as per the local and international markets. This report has been exclusively studied and analyzed by the experts of various domains to meet the success of the reports in the industry.

Get Sample PDF Copy (including COVID19 Impact Analysis, full TOC, Tables, and Figures) of Media for Stem Cell Market Report @ https://www.esherpamarketreports.com/request-sample/es-427598/

The Media for Stem Cell Market Report has answers to all your questions such as:

Key Businesses Segmentation of Media for Stem Cell Market:

By Types, the Media for Stem Cell Market can be Splits into:

By Applications, the Media for Stem Cell Market can be Splits into:

List of Top Key Players of Media for Stem Cell Market:

Thermo Fisher,STEMCELL Technologies,Merck Millipore,Lonza,GE Healthcare,Miltenyi Biotec,PromoCell,Corning,CellGenix,Takara,HiMedia

Enquire before purchasing this report @ https://www.esherpamarketreports.com/pre-order-enquiry/es-427598

Reasons To Buy Media for Stem Cell Market Report :

Purchase this Report with Full Access @ https://www.esherpamarketreports.com/purchase/es-427598/

Media for Stem Cell Market TOC Covers the Following Points:

Chapter 1 Industry Overview 1.1 Definition 1.2 Assumptions 1.3 Research Scope 1.4 Major Country Wise Market Analysis Chapter 2 Major Segmentation (Classification, Application and etc.) Analysis 2.1 Brief Introduction by Major Application 2.2 Brief Introduction by Major Type Chapter 3 Production Market Analysis 3.1 Global Production Market Analysis 3.1.1 2015-2020 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis 3.1.2 2015-2020 Major Manufacturers Performance and Market Share 3.2 Regional Production Market Analysis 3.2.1 2015-2020 Regional Market Performance and Market Share 3.2.2 North America Market 3.2.3 Asia-Pacific Market 3.2.4 Europe Market 3.2.5 Central & South America Market 3.2.6 Middle East & Africa Market 3.2.7 Other Regions Market Chapter 4 Sales Market Analysis 4.1 Global Sales Market Analysis 4.1.1 2015-2020 Global Sales Volume, Sales Price and Sales Revenue Analysis 4.1.2 2015-2020 Major Manufacturers Performance and Market Share 4.2 Regional Sales Market Analysis 4.2.1 2015-2020 Regional Market Performance and Market Share 4.2.2 North America Market 4.2.3 Asia-Pacific Market 4.2.4 Europe Market 4.2.5 Central & South America Market 4.2.6 Middle East & Africa Market 4.2.7 Other Regions Market Chapter 5 Consumption Market Analysis 5.1 Global Consumption Market Analysis

Click Here For Detailed Table Of Contents

Contact Us:

Name: Jason George

Email: [emailprotected]

Call :USA: +1 408 757 0510

Organization: eSherpa Market Reports

About Us:

eSherpa Market Reports is the credible source for gaining the market research reports that will exponentially accelerate your business. We are among the leading report resellers in the business world committed towards optimizing your business. The reports we provide are based on a research that covers a magnitude of factors such as technological evolution, economic shifts and a detailed study of market segment.

Go here to see the original:
Survey: Impact Of Covid-19 On Media for Stem Cell Market 2020 Industry Outlook, Opportunities in Market and Expansion By 2026 - Cole of Duty

BIOBANKS MARKET COMPETITIVE LANDSCAPE ANALYSIS WITH FORECAST BY 2025 – 3rd Watch News

Global Biobanks Market: Overview

The global biobanks market owes its conception to the rising need for replacement organs and the steady advancement in the replacement and transfusion technologies regarding a number of bodily substances. Though the technology and need to store organs and other bio-entities had been available for a long time, the global biobanks market took on a more important role in the healthcare sector following the increasing research in genomics. In the new millennium, the development of the personalized medicine field has been the vital driver for the global biobanks market. The likely advancement of the latter, thanks to helpful government regulations, is likely to make the crucial difference for the global biobanks market in the near future.

The steady technological advancement in the healthcare sector in the last few decades has now led to a scenario where the full potential of biobanks can be harnessed. As a result, the global biobanks market is projected to exhibit steady growth over the coming years.

Global Biobanks Market: Key Trends

The rising interest in personalized medicine is the prime driver for the global biobanks market. Personalized medicine has only become a viable branch of modern medicine after steady research in genomics and the way various patients react to various medicines. The biobanks market has thus come into the spotlight thanks to their role as a steady supplier of human biomaterials for research as well as direct application. The increasing research in genomics following the findings of the Human Genome Project is thus likely to remain a key driver for the global biobanks market in the coming years.

The utilization of biobanks in stem cell research has been hampered in several regions by ethical concerns regarding the origin of stem cells. Nevertheless, the potential of stem cells in the healthcare sector is immense, and is likely to have a decisive impact on the trajectory of the global biobanks market in the coming years. Many countries have, in recent years, adopted a supportive stance towards stem cell research, aiding the growth of the biobanks market. Continued government support is thus likely to remain vital for the global biobanks market in the coming years.

Global Biobanks Market: Market Potential

The leading role of the U.S. in the global biobanks market is unlikely to change in the coming years. The easy availability of government-supported healthcare infrastructure and the presence of several industry giants in the region has driven the biobanks market in the U.S.

Northwell Health, the largest healthcare provider in New York State, earlier in 2017 initiated a new biobank aimed at creating precision therapies against various types of cancer. Launched in collaboration with Indivumed, the biobank will provide catalogued biomaterials for research into lung, colorectal, breast, and pancreatic cancer. This would enable targeted, gene-specific studies of a variety of cancer samples, leading to a more comprehensive understanding of cancer. Such well-funded collaboration efforts are crucial for the developing biobanks market.

Global Biobanks Market: Geographical Dynamics

Led by the fertile healthcare research scenario in the U.S., North America is likely to retain a dominant share in the global biobanks market in the coming years. Steady support from institutes such as the NIH is likely to be vital for the North America biobanks market.

Emerging Asia Pacific economies such as India and China could emerge with a significant share in the global biobanks market in the coming years. The healthcare sector in both countries has received steady public or private funding in the last few years. India is also a global leader in medical tourism and is likely to receive an increasing number of patients in the coming years, leading to promising prospects for the global biobanks market in the region.

Global Biobanks Market: Competitive Dynamics

Due to the dynamic nature of the global biobanks market, with advancements in diagnostic fields often determining the direction of the market, the market is heavily fragmented. It is likely to retain a significant degree of fragmentation in the coming years thanks to the diversity in the application segments of the biobanks market. The leading players in the global biobanks market includeBioCision, Tecan Group, VWR, Beckman Coulter Inc., and Thermo Fisher Scientific.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

More:
BIOBANKS MARKET COMPETITIVE LANDSCAPE ANALYSIS WITH FORECAST BY 2025 - 3rd Watch News

Hematopoietic Stem Cell Transplantation (HSCT) Market Expand Their Businesses With New Investments In 2020 And Coming Future – Bulletin Line

Hematopoietic Stem Cell Transplantation (HSCT) Market report provides (6 Year Forecast 2020-2026) including detailed Coronavirus (COVID-19) impact analysis on Market Size, Regional and Country-Level Market Size, Segmentation Market Growth, Market Share, Competitive Landscape, Sales Analysis and Value Chain Optimization. This Hematopoietic Stem Cell Transplantation (HSCT) market competitive landscape offers details by topmost key manufactures (Regen Biopharma Inc, China Cord Blood Corp, CBR Systems Inc, Escape Therapeutics Inc, Cryo-Save AG, Lonza Group Ltd, Pluristem Therapeutics Inc, ViaCord Inc) including Company Overview, Company Total Revenue (Financials), Market Potential, Presence, Hematopoietic Stem Cell Transplantation (HSCT) industry Sales and Revenue Generated, Market Share, Price, Production Sites and Facilities, SWOT Analysis, Product Launch. For the period 2014-2020, this study provides the Hematopoietic Stem Cell Transplantation (HSCT) sales, revenue and market share for each player covered in this report.

Key Target Audience of Hematopoietic Stem Cell Transplantation (HSCT) Market: Manufacturers of Hematopoietic Stem Cell Transplantation (HSCT), Raw material suppliers, Market research and consulting firms, Government bodies such as regulating authorities and policy makers, Organizations, forums and alliances related to Hematopoietic Stem Cell Transplantation (HSCT) market.

Get Free Sample PDF (including COVID-19 Impact Analysis, full TOC, Tables and Figures)of Hematopoietic Stem Cell Transplantation (HSCT)[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2276986

Synopsis of Hematopoietic Stem Cell Transplantation (HSCT) Market:In 2019, the market size of Hematopoietic Stem Cell Transplantation (HSCT) is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Hematopoietic Stem Cell Transplantation (HSCT).

Based onProduct Type, Hematopoietic Stem Cell Transplantation (HSCT) market report displays the manufacture, profits, value, and market segment and growth rate of each type, covers:

Allogeneic Autologous

Based onend users/applications, Hematopoietic Stem Cell Transplantation (HSCT) market report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, this can be divided into:

Peripheral Blood Stem Cells Transplant (PBSCT) Bone Marrow Transplant (BMT) Cord Blood Transplant (CBT)

Hematopoietic Stem Cell Transplantation (HSCT) Market: Regional analysis includes:

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2276986

The Hematopoietic Stem Cell Transplantation (HSCT) Market Report Can Answer The Following Questions:

What are the Upstream Raw Materials And Manufacturing Equipment of Hematopoietic Stem Cell Transplantation (HSCT)? What is the manufacturing process of Hematopoietic Stem Cell Transplantation (HSCT)?

Who are the key manufacturers of Hematopoietic Stem Cell Transplantation (HSCT) market? How are their operating situation (Capacity, Production, Price, Cost, Gross and Revenue)?

Economic impact on Hematopoietic Stem Cell Transplantation (HSCT) industry and development trend of Hematopoietic Stem Cell Transplantation (HSCT) industry.

What is the (North America, South America, Europe, Africa, Middle East, Asia, China, Japan) Production, Production Value, Consumption, Consumption Value, Import And Export of Hematopoietic Stem Cell Transplantation (HSCT)?

What will the Hematopoietic Stem Cell Transplantation (HSCT) Market Size and The Growth Rate be in 2026?

What are the key market trends impacting the growth of the Hematopoietic Stem Cell Transplantation (HSCT) market?

What are the Hematopoietic Stem Cell Transplantation (HSCT) Market Challenges to market growth?

What are the types and applications of Hematopoietic Stem Cell Transplantation (HSCT)? What is the market share of each type and application?

What are the key factors driving the Hematopoietic Stem Cell Transplantation (HSCT) market?

What are the Hematopoietic Stem Cell Transplantation (HSCT) market opportunities and threats faced by the vendors in the Hematopoietic Stem Cell Transplantation (HSCT) market?

Contact:

ResearchMoz Mr. Rohit Bhisey, Tel: +1-518-621-2074 USA-Canada Toll Free: 866-997-4948 Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

Here is the original post:
Hematopoietic Stem Cell Transplantation (HSCT) Market Expand Their Businesses With New Investments In 2020 And Coming Future - Bulletin Line

Stem Cell Banking Market Report (2020-2025) | The Demand For The Market Will Drastically Increase In The Future – 3rd Watch News

The global Stem Cell Banking market was valued at USD 1.52 billion in 2016 and is projected to reach USD 7.94 billion by 2025, growing at a CAGR of 20.17% from 2017 to 2025.

View Source Of Related Reports:

Viral Inactivation Market Virus Filtration Market Viral Clearance Market Veterinary-Animal Vaccines Market Vaccine Adjuvants Market Terahertz and Infrared Spectroscopy Market Tangential Flow Filtration Market Sterile Filtration Market Stem Cell Banking Market

Stem Cell banking involves preservation of new born placental stem cells or amniotic stem cells as well as adult bone marrow stem cells. The concept ensures health safety in case of a major surgery or organ regeneration needs for the patient. With increasing awareness regarding the practice, the market is expected to boost in near future.

The Final Report will cover the impact analysis of COVID-19 on this industry:

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10008449

Sample Infographics:

Market Dynamics: 1. Market Drivers 1.1 Easy Extraction Methods 1.2 High birth ratio 1.3 Increase in GDP and Disposable income in developing nations 1.4 Increasing support from public and private sector 1.5 Scope of stem cell usage in therapeutics and treatment 2. Market Restraints 2.1 Large number of players in the market 2.2 High Cost of technology 2.3 Lack of awareness 2.4 Regulatory restrains

Market Segmentation: 1. By Application: 1.1 Cerebral Palsy 1.2 Thalassemia 1.3 Leukemia 1.4 Diabetes 1.5 Autism 1.6 Others

2. By Services: 2.1 Collection & Transportation 2.2 Processing 2.3 Analysis 2.4 Storage

3. By Bank Type: 3.1 Cord Blood 3.2 Cord Tissue

4. By Region: 4.1 North America (U.S., Canada, Mexico) 4.2 Europe (Germany, UK, France, Rest of Europe) 4.3 Asia Pacific (China, India, Japan, Rest of Asia Pacific) 4.4 Latin America (Brazil, Argentina, Rest of Latin America) 4.5 Middle East & Africa

Competitive Landscape: The major players in the market are as follows: 1.CBR Systems, Inc. 2. Cordlife 3. Cryo-Cell 4. Cryo-Save AG (A Group of Esperite) 5. Lifecell 6. Stemcyte 7. Viacord 8. Smart Cells International Ltd. 9. Cryoviva India 10. Cordvida 11. China Cord Blood Corporation These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.

Request For Full Report:https://www.kennethresearch.com/sample-request-10008449

RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE:Research study on the Stem Cell Bankingmarketwas performed in five phases which include Secondary research, Primary research, subject matter expert advice, quality check and final review. The market data was analyzed and forecasted using market statistical and coherent models. Also market shares and key trends were taken into consideration while making the report. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis.

To know more about the Research Methodology of Verified Market Intelligence and other aspects of the research study, kindly get in touch with our sales team.

About Kenneth Research:

Kenneth Research provides market research reports to different individuals, industries, associations and organizations with an aim of helping them to take prominent decisions. Our research library comprises of more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both macro level as well as micro level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis on various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keep a track on the international and domestic market for any economic changes impacting the products demand, growth and opportunities for new and existing players.

Contact Us

Kenneth Research

Email:[emailprotected]

Phone: +1 313 462 0609

Read the original:
Stem Cell Banking Market Report (2020-2025) | The Demand For The Market Will Drastically Increase In The Future - 3rd Watch News

FDA Approves Merck’s KEYTRUDA (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that…

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Mercks anti-PD-1 therapy, as monotherapy for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation. This approval is based on data from the Phase 2 KEYNOTE-629 trial, in which KEYTRUDA demonstrated meaningful efficacy and durability of response, with an objective response rate (ORR) of 34% (95% CI, 25-44), including a complete response rate of 4% and a partial response rate of 31%. Among responding patients, 69% had ongoing responses of six months or longer. After a median follow-up time of 9.5 months, the median duration of response (DOR) had not been reached (range, 2.7 to 13.1+ months).

Cutaneous squamous cell carcinoma is the second most common form of skin cancer, said Dr. Jonathan Cheng, vice president, clinical research, Merck Research Laboratories. In KEYNOTE-629, treatment with KEYTRUDA resulted in clinically meaningful and durable responses. Todays approval is great news for patients with cSCC and further demonstrates our commitment to bringing new treatment options to patients with advanced, difficult-to-treat cancers.

Immune-mediated adverse reactions, which may be severe or fatal, can occur with KEYTRUDA, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis and renal dysfunction, severe skin reactions, solid organ transplant rejection, and complications of allogeneic hematopoietic stem cell transplantation (HSCT). Based on the severity of the adverse reaction, KEYTRUDA should be withheld or discontinued and corticosteroids administered if appropriate. KEYTRUDA can also cause severe or life-threatening infusion-related reactions. Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. For more information, see Selected Important Safety Information below.

Data Supporting Approval

The efficacy of KEYTRUDA was investigated in patients with recurrent or metastatic cSCC enrolled in KEYNOTE-629 (NCT03284424), a multi-center, multi-cohort, non-randomized, open-label trial. The trial excluded patients with autoimmune disease or a medical condition that required immunosuppression. The major efficacy outcome measures were ORR and DOR as assessed by blinded independent central review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, modified to follow a maximum of 10 target lesions and a maximum of five target lesions per organ.

Among the 105 patients treated, 87% received one or more prior lines of therapy and 74% received prior radiation therapy. Forty-five percent of patients had locally recurrent only cSCC, 24% had metastatic only cSCC and 31% had both locally recurrent and metastatic cSCC. The study population characteristics were: median age of 72 years (range, 29 to 95); 71% age 65 or older; 76% male; 71% White; 25% race unknown; 34% Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 and 66% ECOG PS of 1.

KEYTRUDA demonstrated an ORR of 34% (95% CI, 25-44) with a complete response rate of 4% and a partial response rate of 31%. Among the 36 responding patients, 69% had ongoing responses of six months or longer. After a median follow-up time of 9.5 months, the median DOR had not been reached (range, 2.7 to 13.1+ months).

Patients received KEYTRUDA 200 mg intravenously every three weeks until documented disease progression, unacceptable toxicity or a maximum of 24 months. Patients with initial radiographic disease progression could receive additional doses of KEYTRUDA during confirmation of progression unless disease progression was symptomatic, rapidly progressive, required urgent intervention, or occurred with a decline in performance status. Assessment of tumor status was performed every six weeks during the first year and every nine weeks during the second year.

Among the 105 patients with cSCC enrolled in KEYNOTE-629, the median duration of exposure to KEYTRUDA was 5.8 months (range, 1 day to 16.1 months). Patients with autoimmune disease or a medical condition that required systemic corticosteroids or other immunosuppressive medications were ineligible. Adverse reactions occurring in patients with cSCC were similar to those occurring in 2,799 patients with melanoma or non-small cell lung cancer (NSCLC) treated with KEYTRUDA as a single agent. Laboratory abnormalities (Grades 3-4) that occurred at a higher incidence included lymphopenia (11%).

About KEYTRUDA (pembrolizumab) Injection, 100 mg

KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of the bodys immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.

Merck has the industrys largest immuno-oncology clinical research program. There are currently more than 1,200 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient's likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.

Selected KEYTRUDA (pembrolizumab) Indications

Melanoma

KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.

KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.

Non-Small Cell Lung Cancer

KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.

KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.

KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [tumor proportion score (TPS) 1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.

KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS 1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.

Small Cell Lung Cancer

KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least 1 other prior line of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Head and Neck Squamous Cell Cancer

KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).

KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [combined positive score (CPS) 1] as determined by an FDA-approved test.

KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy.

Classical Hodgkin Lymphoma

KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Primary Mediastinal Large B-Cell Lymphoma

KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.

Urothelial Carcinoma

KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 [combined positive score (CPS) 10], as determined by an FDA-approved test, or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

KEYTRUDA is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

Microsatellite Instability-High (MSI-H) Cancer

KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established.

Gastric Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS 1) as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Esophageal Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS 10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.

Cervical Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS 1) as determined by an FDA-approved test. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Hepatocellular Carcinoma

KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Merkel Cell Carcinoma

KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Renal Cell Carcinoma

KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

Tumor Mutational Burden-High Cancer

KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established.

Cutaneous Squamous Cell Carcinoma

KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.

Selected Important Safety Information for KEYTRUDA

Immune-Mediated Pneumonitis

KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases. Pneumonitis occurred in 3.4% (94/2799) of patients with various cancers receiving KEYTRUDA, including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%). Pneumonitis occurred in 8.2% (65/790) of NSCLC patients receiving KEYTRUDA as a single agent, including Grades 3-4 in 3.2% of patients, and occurred more frequently in patients with a history of prior thoracic radiation (17%) compared to those without (7.7%). Pneumonitis occurred in 6% (18/300) of HNSCC patients receiving KEYTRUDA as a single agent, including Grades 3-5 in 1.6% of patients, and occurred in 5.4% (15/276) of patients receiving KEYTRUDA in combination with platinum and FU as first-line therapy for advanced disease, including Grades 3-5 in 1.5% of patients.

Monitor patients for signs and symptoms of pneumonitis. Evaluate suspected pneumonitis with radiographic imaging. Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or recurrent Grade 2 pneumonitis.

Immune-Mediated Colitis

KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 1.7% (48/2799) of patients receiving KEYTRUDA, including Grade 2 (0.4%), 3 (1.1%), and 4 (<0.1%). Monitor patients for signs and symptoms of colitis. Administer corticosteroids for Grade 2 or greater colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for Grade 4 colitis.

Immune-Mediated Hepatitis (KEYTRUDA) and Hepatotoxicity (KEYTRUDA in Combination With Axitinib)

Immune-Mediated Hepatitis

KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 0.7% (19/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3 (0.4%), and 4 (<0.1%). Monitor patients for changes in liver function. Administer corticosteroids for Grade 2 or greater hepatitis and, based on severity of liver enzyme elevations, withhold or discontinue KEYTRUDA.

Hepatotoxicity in Combination With Axitinib

KEYTRUDA in combination with axitinib can cause hepatic toxicity with higher than expected frequencies of Grades 3 and 4 ALT and AST elevations compared to KEYTRUDA alone. With the combination of KEYTRUDA and axitinib, Grades 3 and 4 increased ALT (20%) and increased AST (13%) were seen. Monitor liver enzymes before initiation of and periodically throughout treatment. Consider more frequent monitoring of liver enzymes as compared to when the drugs are administered as single agents. For elevated liver enzymes, interrupt KEYTRUDA and axitinib, and consider administering corticosteroids as needed.

Immune-Mediated Endocrinopathies

KEYTRUDA can cause adrenal insufficiency (primary and secondary), hypophysitis, thyroid disorders, and type 1 diabetes mellitus. Adrenal insufficiency occurred in 0.8% (22/2799) of patients, including Grade 2 (0.3%), 3 (0.3%), and 4 (<0.1%). Hypophysitis occurred in 0.6% (17/2799) of patients, including Grade 2 (0.2%), 3 (0.3%), and 4 (<0.1%). Hypothyroidism occurred in 8.5% (237/2799) of patients, including Grade 2 (6.2%) and 3 (0.1%). The incidence of new or worsening hypothyroidism was higher in 1185 patients with HNSCC (16%) receiving KEYTRUDA, as a single agent or in combination with platinum and FU, including Grade 3 (0.3%) hypothyroidism. Hyperthyroidism occurred in 3.4% (96/2799) of patients, including Grade 2 (0.8%) and 3 (0.1%), and thyroiditis occurred in 0.6% (16/2799) of patients, including Grade 2 (0.3%). Type 1 diabetes mellitus, including diabetic ketoacidosis, occurred in 0.2% (6/2799) of patients.

Monitor patients for signs and symptoms of adrenal insufficiency, hypophysitis (including hypopituitarism), thyroid function (prior to and periodically during treatment), and hyperglycemia. For adrenal insufficiency or hypophysitis, administer corticosteroids and hormone replacement as clinically indicated. Withhold KEYTRUDA for Grade 2 adrenal insufficiency or hypophysitis and withhold or discontinue KEYTRUDA for Grade 3 or Grade 4 adrenal insufficiency or hypophysitis. Administer hormone replacement for hypothyroidism and manage hyperthyroidism with thionamides and beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism. Administer insulin for type 1 diabetes, and withhold KEYTRUDA and administer antihyperglycemics in patients with severe hyperglycemia.

Immune-Mediated Nephritis and Renal Dysfunction

KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 0.3% (9/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3 (0.1%), and 4 (<0.1%) nephritis. Nephritis occurred in 1.7% (7/405) of patients receiving KEYTRUDA in combination with pemetrexed and platinum chemotherapy. Monitor patients for changes in renal function. Administer corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for Grade 2; permanently discontinue for Grade 3 or 4 nephritis.

Immune-Mediated Skin Reactions

Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative dermatitis, and bullous pemphigoid, can occur. Monitor patients for suspected severe skin reactions and based on the severity of the adverse reaction, withhold or permanently discontinue KEYTRUDA and administer corticosteroids. For signs or symptoms of SJS or TEN, withhold KEYTRUDA and refer the patient for specialized care for assessment and treatment. If SJS or TEN is confirmed, permanently discontinue KEYTRUDA.

Other Immune-Mediated Adverse Reactions

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue in patients receiving KEYTRUDA and may also occur after discontinuation of treatment. For suspected immune-mediated adverse reactions, ensure adequate evaluation to confirm etiology or exclude other causes. Based on the severity of the adverse reaction, withhold KEYTRUDA and administer corticosteroids. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Based on limited data from clinical studies in patients whose immune-related adverse reactions could not be controlled with corticosteroid use, administration of other systemic immunosuppressants can be considered. Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less following corticosteroid taper. Permanently discontinue KEYTRUDA for any Grade 3 immune-mediated adverse reaction that recurs and for any life-threatening immune-mediated adverse reaction.

The following clinically significant immune-mediated adverse reactions occurred in less than 1% (unless otherwise indicated) of 2799 patients: arthritis (1.5%), uveitis, myositis, Guillain-Barr syndrome, myasthenia gravis, vasculitis, pancreatitis, hemolytic anemia, sarcoidosis, and encephalitis. In addition, myelitis and myocarditis were reported in other clinical trials, including classical Hodgkin lymphoma, and postmarketing use.

Treatment with KEYTRUDA may increase the risk of rejection in solid organ transplant recipients. Consider the benefit of treatment vs the risk of possible organ rejection in these patients.

Infusion-Related Reactions

KEYTRUDA can cause severe or life-threatening infusion-related reactions, including hypersensitivity and anaphylaxis, which have been reported in 0.2% (6/2799) of patients. Monitor patients for signs and symptoms of infusion-related reactions. For Grade 3 or 4 reactions, stop infusion and permanently discontinue KEYTRUDA.

Complications of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Immune-mediated complications, including fatal events, occurred in patients who underwent allogeneic HSCT after treatment with KEYTRUDA. Of 23 patients with cHL who proceeded to allogeneic HSCT after KEYTRUDA, 6 (26%) developed graft-versus-host disease (GVHD) (1 fatal case) and 2 (9%) developed severe hepatic veno-occlusive disease (VOD) after reduced-intensity conditioning (1 fatal case). Cases of fatal hyperacute GVHD after allogeneic HSCT have also been reported in patients with lymphoma who received a PD-1 receptorblocking antibody before transplantation. Follow patients closely for early evidence of transplant-related complications such as hyperacute graft-versus-host disease (GVHD), Grade 3 to 4 acute GVHD, steroid-requiring febrile syndrome, hepatic veno-occlusive disease (VOD), and other immune-mediated adverse reactions.

In patients with a history of allogeneic HSCT, acute GVHD (including fatal GVHD) has been reported after treatment with KEYTRUDA. Patients who experienced GVHD after their transplant procedure may be at increased risk for GVHD after KEYTRUDA. Consider the benefit of KEYTRUDA vs the risk of GVHD in these patients.

Increased Mortality in Patients With Multiple Myeloma

In trials in patients with multiple myeloma, the addition of KEYTRUDA to a thalidomide analogue plus dexamethasone resulted in increased mortality. Treatment of these patients with a PD-1 or PD-L1 blocking antibody in this combination is not recommended outside of controlled trials.

Embryofetal Toxicity

Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. Advise women of this potential risk. In females of reproductive potential, verify pregnancy status prior to initiating KEYTRUDA and advise them to use effective contraception during treatment and for 4 months after the last dose.

Adverse Reactions

In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9% of 555 patients with advanced melanoma; adverse reactions leading to permanent discontinuation in more than one patient were colitis (1.4%), autoimmune hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and cardiac failure (0.4%). The most common adverse reactions (20%) with KEYTRUDA were fatigue (28%), diarrhea (26%), rash (24%), and nausea (21%).

In KEYNOTE-002, KEYTRUDA was permanently discontinued due to adverse reactions in 12% of 357 patients with advanced melanoma; the most common (1%) were general physical health deterioration (1%), asthenia (1%), dyspnea (1%), pneumonitis (1%), and generalized edema (1%). The most common adverse reactions were fatigue (43%), pruritus (28%), rash (24%), constipation (22%), nausea (22%), diarrhea (20%), and decreased appetite (20%).

In KEYNOTE-054, KEYTRUDA was permanently discontinued due to adverse reactions in 14% of 509 patients; the most common (1%) were pneumonitis (1.4%), colitis (1.2%), and diarrhea (1%). Serious adverse reactions occurred in 25% of patients receiving KEYTRUDA. The most common adverse reaction (20%) with KEYTRUDA was diarrhea (28%).

In KEYNOTE-189, when KEYTRUDA was administered with pemetrexed and platinum chemotherapy in metastatic nonsquamous NSCLC, KEYTRUDA was discontinued due to adverse reactions in 20% of 405 patients. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA were pneumonitis (3%) and acute kidney injury (2%). The most common adverse reactions (20%) with KEYTRUDA were nausea (56%), fatigue (56%), constipation (35%), diarrhea (31%), decreased appetite (28%), rash (25%), vomiting (24%), cough (21%), dyspnea (21%), and pyrexia (20%).

In KEYNOTE-407, when KEYTRUDA was administered with carboplatin and either paclitaxel or paclitaxel protein-bound in metastatic squamous NSCLC, KEYTRUDA was discontinued due to adverse reactions in 15% of 101 patients. The most frequent serious adverse reactions reported in at least 2% of patients were febrile neutropenia, pneumonia, and urinary tract infection. Adverse reactions observed in KEYNOTE-407 were similar to those observed in KEYNOTE-189 with the exception that increased incidences of alopecia (47% vs 36%) and peripheral neuropathy (31% vs 25%) were observed in the KEYTRUDA and chemotherapy arm compared to the placebo and chemotherapy arm in KEYNOTE-407.

In KEYNOTE-042, KEYTRUDA was discontinued due to adverse reactions in 19% of 636 patients with advanced NSCLC; the most common were pneumonitis (3%), death due to unknown cause (1.6%), and pneumonia (1.4%). The most frequent serious adverse reactions reported in at least 2% of patients were pneumonia (7%), pneumonitis (3.9%), pulmonary embolism (2.4%), and pleural effusion (2.2%). The most common adverse reaction (20%) was fatigue (25%).

In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse reactions in 8% of 682 patients with metastatic NSCLC; the most common was pneumonitis (1.8%). The most common adverse reactions (20%) were decreased appetite (25%), fatigue (25%), dyspnea (23%), and nausea (20%).

Adverse reactions occurring in patients with SCLC were similar to those occurring in patients with other solid tumors who received KEYTRUDA as a single agent.

In KEYNOTE-048, KEYTRUDA monotherapy was discontinued due to adverse events in 12% of 300 patients with HNSCC; the most common adverse reactions leading to permanent discontinuation were sepsis (1.7%) and pneumonia (1.3%). The most common adverse reactions (20%) were fatigue (33%), constipation (20%), and rash (20%).

In KEYNOTE-048, when KEYTRUDA was administered in combination with platinum (cisplatin or carboplatin) and FU chemotherapy, KEYTRUDA was discontinued due to adverse reactions in 16% of 276 patients with HNSCC. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA were pneumonia (2.5%), pneumonitis (1.8%), and septic shock (1.4%). The most common adverse reactions (20%) were nausea (51%), fatigue (49%), constipation (37%), vomiting (32%), mucosal inflammation (31%), diarrhea (29%), decreased appetite (29%), stomatitis (26%), and cough (22%).

In KEYNOTE-012, KEYTRUDA was discontinued due to adverse reactions in 17% of 192 patients with HNSCC. Serious adverse reactions occurred in 45% of patients. The most frequent serious adverse reactions reported in at least 2% of patients were pneumonia, dyspnea, confusional state, vomiting, pleural effusion, and respiratory failure. The most common adverse reactions (20%) were fatigue, decreased appetite, and dyspnea. Adverse reactions occurring in patients with HNSCC were generally similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy, with the exception of increased incidences of facial edema and new or worsening hypothyroidism.

In KEYNOTE-087, KEYTRUDA was discontinued due to adverse reactions in 5% of 210 patients with cHL. Serious adverse reactions occurred in 16% of patients; those 1% included pneumonia, pneumonitis, pyrexia, dyspnea, GVHD, and herpes zoster. Two patients died from causes other than disease progression; 1 from GVHD after subsequent allogeneic HSCT and 1 from septic shock. The most common adverse reactions (20%) were fatigue (26%), pyrexia (24%), cough (24%), musculoskeletal pain (21%), diarrhea (20%), and rash (20%).

In KEYNOTE-170, KEYTRUDA was discontinued due to adverse reactions in 8% of 53 patients with PMBCL. Serious adverse reactions occurred in 26% of patients and included arrhythmia (4%), cardiac tamponade (2%), myocardial infarction (2%), pericardial effusion (2%), and pericarditis (2%). Six (11%) patients died within 30 days of start of treatment. The most common adverse reactions (20%) were musculoskeletal pain (30%), upper respiratory tract infection and pyrexia (28% each), cough (26%), fatigue (23%), and dyspnea (21%).

Link:
FDA Approves Merck's KEYTRUDA (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that...

Global 3D Cell Culture Market (2019-2024) with COVID-19 After Effects Analysis by Emerging Trends, Industry Demand, Growth, Key Players – Cole of Duty

Global 3D Cell Culture Market 2020 report presents an overview of the market on the basis of key parameters such as market size, revenue, sales analysis and key drivers. The market size of global 3D Cell Culture market is anticipated to grow at large scale over the forecast period from 2020 to 2024. The main purpose of the study report is to give users an extensive viewpoint of the market. So that users can apply strategic processes to benchmark themselves against rest of the world. Key drivers as well as challenges of the market are discussed in the report. Also reports provides an in depth analysis of the 3D Cell Culture market with current and future trends.

Top Leading Key Players are:

Thermo Fisher Scientific Corning Lonza Group Kuraray Co Merck Kgaa Insphero N3d Bioscience Reprocell Incorporated 3D Biotek

Get Sample Copy of the Report @ https://www.reportspedia.com/report/life-sciences/global-3d-cell-culture-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/2238 #request_sample

In addition, study report suggests an array of opportunities for the players participating in the industry. This ultimately leads into the growth of the global 3D Cell Culture market. Furthermore, report offers a comprehensive study on market size, revenue, sales, growth factors and risks involved in the growth of the market during the forecast period. The factors which are influencing the growth the market are mentioned in the report as well as the challenges which can hamper the growth of the 3D Cell Culture market over the forecast period.

The main objective of this research report is to present the comprehensive analysis about the factors which are responsible for the growth of the global 3D Cell Culture market. The study report covers all the recent developments and innovations in the market. The global keyword market is likely to provide insights for the major strategies which is also estimated to have an impact on the overall growth of the market. Several strategies such as the PESTEL analysis and SWOT analysis is also being covered for the global market. These strategies have an impact on the overall 3D Cell Culture market.

Hurry Up!!!To get a Massive Discount Just Click @ https://www.reportspedia.com/discount_inquiry/discount/2238

Global 3D Cell Culture market is segmented based by type, application and region.

Segmentation Based on Type,

Scaffold-based Scaffold-free

Segmentation Based on application,

Cancer Research Stem Cell Research Drug Discovery Regererative Medicine

The research report on global 3D Cell Culture market ensures users to remain competitive in the market. Also report helps to identify the new innovations and developments by existing key players to increase the growth of the global 3D Cell Culture market.

Inquiry Here for the Report Click @: https://www.reportspedia.com/report/life-sciences/global-3d-cell-culture-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/2238 #inquiry_before_buying

Study report covers all the geographical regions where competitive landscape exists by the players such as: North America, Europe, Latin America, Asia-Pacific and Middle East Africa. Thus report helps to identify the key growth countries and regions.

In addition, report presents quantitative as well as qualitative narration of global 3D Cell Culture market. The research report is beneficial for educators, researchers, strategy managers, academic institutions and analysts. Thus report helps all types of users to identify the strategic initiatives so that they can understand how to expand the global 3D Cell Culture market business across the globe for the product development. Moreover, research report provides in depth analysis of all the segments which can impact on the market growth.

View Report TOC In detail: https://www.reportspedia.com/report/life-sciences/global-3d-cell-culture-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/2238 #table_of_contents

Read the rest here:
Global 3D Cell Culture Market (2019-2024) with COVID-19 After Effects Analysis by Emerging Trends, Industry Demand, Growth, Key Players - Cole of Duty

Global Cell Expansion Supporting Equipment Market Research with COVID-19 After Effects – Cole of Duty

Researchstore.biz has published an exclusive report named Global Cell Expansion Supporting Equipment Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 which consists of overall market scenario with prevalent and future growth prospects. The report delivers the analytical elaboration and other industry-linked information in an aim to supply specific and reliable analysis on the global Cell Expansion Supporting Equipment market. The report focuses on market dynamics, growth-driving factors, restraints, and limitations this market is currently facing and is expected to face in the coming years (2020-2025). The report is further divided by company, by country, and by application/types for the competitive landscape analysis. It estimates production chain, manufacturing capacity, sales volume, and revenue.

The report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive landscape, sales analysis, the impact of domestic and global market players. It contains advanced information associated with the global Cell Expansion Supporting Equipment market status, trends analysis, segment, and forecasts from 2020-2025. It explains market scenarios, comparative pricing between major players, cost, and profit of the specified market regions.

NOTE: This report takes into account the current and future impacts of COVID-19 on this industry and offers you an in-dept analysis of Cell Expansion Supporting Equipment market.

DOWNLOAD FREE SAMPLE REPORT: https://www.researchstore.biz/sample-request/30516

Key Players Analysis:

The report analyzes the top manufacturers, exporters, and retailers (if applicable) around the world concerning their company profile, product portfolio, capacity, price, cost, and revenue. For competitor segment, the report covers the following global Cell Expansion Supporting Equipment market key players and some other small players: Beckman Coulter, Inc. (U.S.), STEMCELL Technologies, Inc. (Canada), GE Healthcare (U.K.), Becton, Dickinson and Company (U.S.), Miltenyi Biotec (Germany), Corning, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), Lonza (Switzerland), Terumo BCT, Inc. (U.S.)

In market segmentation by types, the report covers: Flow cytometer, Cell counters, Centrifuges, Others,

In market segmentation by applications, the report covers the following uses: Regenerative Medicine and Stem Cell Research, Cancer and Cell-based Research, Others,

Regionally, this report focuses on several key regions: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Moreover, the report exhaustively investigates business opportunities, market scope, threats, and barriers. The report aims to help companies in strategizing their decisions in a better way and finally attains their business goals. The research answers important business questions like how the global Cell Expansion Supporting Equipment market will perform in the existing market scenario. It also presents the potential industry supply, market demand, market value, market competition, key market players, and the industry estimate from 2020-2025.

ACCESS FULL REPORT: https://www.researchstore.biz/report/global-cell-expansion-supporting-equipment-market-30516

Important Key Questions Answered In The Market Report:

Customization of the Report: This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Researchstore.biz is a fully dedicated global market research agency providing thorough quantitative and qualitative analysis of extensive market research.Our corporate is identified by recognition and enthusiasm for what it offers, which unites its staff across the world.We are desired market researchers proving a reliable source of extensive market analysis on which readers can rely on. Our research team consist of some of the best market researchers, sector and analysis executives in the nation, because of which Researchstore.biz is considered as one of the most vigorous market research enterprises. Researchstore.biz finds perfect solutions according to the requirements of research with considerations of content and methods. Unique and out of the box technologies, techniques and solutions are implemented all through the research reports.

Contact Us Mark Stone Head of Business Development Phone: +1-201-465-4211 Email: [emailprotected] Web: http://www.researchstore.biz

Read this article:
Global Cell Expansion Supporting Equipment Market Research with COVID-19 After Effects - Cole of Duty

Stem Cell And Regenerative Therapy Market : Segmentation, Industry Trends and Development size COVID-19 2024 – 3rd Watch News

he globalstem cell and regenerative medicines marketshould grow from $21.8 billion in 2019 to reach $55.0 billion by 2024 at a compound annual growth rate (CAGR) of 20.4% for the period of 2019-2024.

Report Scope:

The scope of this report is broad and covers various type of product available in the stem cell and regenerative medicines market and potential application sectors across various industries. The current report offers a detailed analysis of the stem cell and regenerative medicines market.

The report highlights the current and future market potential of stem cell and regenerative medicines and provides a detailed analysis of the competitive environment, recent development, merger and acquisition, drivers, restraints, and technology background in the market. The report also covers market projections through 2024.

The report details market shares of stem cell and regenerative medicines based on products, application, and geography. Based on product the market is segmented into therapeutic products, cell banking, tools and reagents. The therapeutics products segments include cell therapy, tissue engineering and gene therapy. By application, the market is segmented into oncology, cardiovascular disorders, dermatology, orthopedic applications, central nervous system disorders, diabetes, others

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Request for Report Sample:https://www.trendsmarketresearch.com/report/sample/11723

Report Includes:

28 data tables An overview of global markets for stem cell and regenerative medicines Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024 Details of historic background and description of embryonic and adult stem cells Information on stem cell banking and stem cell research A look at the growing research & development activities in regenerative medicine Coverage of ethical issues in stem cell research & regulatory constraints on biopharmaceuticals Comprehensive company profiles of key players in the market, including Aldagen Inc., Caladrius Biosciences Inc., Daiichi Sankyo Co. Ltd., Gamida Cell Ltd. and Novartis AG

Summary

The global market for stem cell and regenerative medicines was valued at REDACTED billion in 2018. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach approximately REDACTED billion by 2024. Growth of the global market is attributed to the factors such as growingprevalence of cancer, technological advancement in product, growing adoption of novel therapeuticssuch as cell therapy, gene therapy in treatment of chronic diseases and increasing investment fromprivate players in cell-based therapies.

In the global market, North America held the highest market share in 2018. The Asia-Pacific region is anticipated to grow at the highest CAGR during the forecast period. The growing government funding for regenerative medicines in research institutes along with the growing number of clinical trials based on cell-based therapy and investment in R&D activities is expected to supplement the growth of the stem cell and regenerative market in Asia-Pacific region during the forecast period.

Reasons for Doing This Study

Global stem cell and regenerative medicines market comprises of various products for novel therapeutics that are adopted across various applications. New advancement and product launches have influenced the stem cell and regenerative medicines market and it is expected to grow in the near future. The biopharmaceutical companies are investing significantly in cell-based therapeutics. The government organizations are funding research and development activities related to stem cell research. These factors are impacting the stem cell and regenerative medicines market positively and augmenting the demand of stem cell and regenerative therapy among different application segments. The market is impacted through adoption of stem cell therapy. The key players in the market are investing in development of innovative products. The stem cell therapy market is likely to grow during the forecast period owing to growing investment from private companies, increasing in regulatory approval of stem cell-based therapeutics for treatment of chronic diseases and growth in commercial applications of regenerative medicine.

Products based on stem cells do not yet form an established market, but unlike some other potential applications of bioscience, stem cell technology has already produced many significant products in important therapeutic areas. The potential scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its current practical applications, evaluate the participating companies and look to its future.

The report provides the reader with a background on stem cell and regenerative therapy, analyzes the current factors influencing the market, provides decision-makers the tools that inform decisions about expansion and penetration in this market.

More Info of Impact[emailprotected]https://www.trendsmarketresearch.com/report/covid-19-analysis/11723

Read more here:
Stem Cell And Regenerative Therapy Market : Segmentation, Industry Trends and Development size COVID-19 2024 - 3rd Watch News